uBiome Releases New Explorer™ Story for Alcohol Metabolism
SAN FRANCISCO, Jan. 7, 2019
SAN FRANCISCO, Jan. 7, 2019 /PRNewswire-PRWeb/ -- uBiome, the leader in microbial genomics, announced today the release of a new Explorer™ story which provides insights to help individuals understand how their gut microbes offer support in metabolizing alcohol.
In the process of metabolizing alcohol, your microbiome may play a role in how long the toxic byproducts of breakdown linger in your body. The new story provides an individualized abundance of two groups of gut microbes–those that help toxic acetaldehyde accumulate, and those that help break it down–and concrete ways to improve the levels of both.
"The first product we launched, Explorer offers consumers a unique look at the microscopic inhabitants that live in and on their bodies," Dr. Jessica Richman, PhD, co-founder and CEO of uBiome, said. "As the research evolves, we are constantly expanding the insights it provides, giving individuals a more comprehensive breakdown of their microbiome, how it's functioning, and how it compares to others."
Since its launch in 2013, Explorer, uBiome's pioneer product, has provided consumers with a tool to understand how their diet and lifestyle play a role in their health and wellness. It is the world's first microbiome test to use next-generation sequencing, allowing consumers to learn about their microbiomes from the comfort of their homes. With the health and wellness market surpassing $37 trillion globally, Explorer targets biohackers, fitness enthusiasts, and consumers interested in a comprehensive breakdown of their microbiome, how it's functioning, and how it compares to others. Explorer currently offers information on how microbes may alter gluten sensitivity, inflammation, lactose intolerance, healthy weight, and metabolism. To learn more about your own microbiome, visit https://ubiome.com/consumer/ubiome-explorer/.
Founded in 2012, uBiome is the leader in microbial genomics. The Company's mission is to advance the science of the microbiome and make it useful to people. uBiome combines its patented proprietary precision sequencing™ with machine learning and artificial intelligence to develop wellness products, clinical tests, and therapeutic targets. uBiome has filed for over 250 patents on its technology, which includes sample preparation, computational analysis, molecular techniques, as well as diagnostic and therapeutic applications.
uBiome's commercial products include SmartGut™, the world's first sequencing-based clinical microbiome test, which identifies microbes in the gut for patients with chronic gut conditions such as IBD, IBS, Crohn's Disease, and ulcerative colitis; SmartJane™, the first sequencing-based women's health screening test, which genotypes all 19 clinically relevant strains of HPV, identifies four common STDs, and surveys more than 20 vaginal microbes associated with bacterial vaginosis and other conditions; SmartFlu™, the world's first sequencing-based clinical respiratory test, which identifies more than 20 clinically relevant targets for viruses and bacteria associated with the flu and common cold; and Explorer™, a health and wellness product to understand the role that food and lifestyle can play in wellness.
uBiome's platform has been used by hundreds of thousands of consumers, patients, and doctors and more than 200 research institutions around the world, including the US Centers for Disease Control (CDC), US National Institutes of Health (NIH), Harvard University, Stanford University, the Massachusetts Institute of Technology (MIT), University of California, San Francisco, Oxford University, and the University of Sydney.
Since its launch, the company has received widespread recognition including CNN 10: Startups to Watch, the IVY Technology Award, CNN Future 30, and was named one of Fast Company's Most Innovative Companies in Healthcare in 2016 and in Data Science in 2018, as well as a Technology Pioneer from the World Economic Forum in 2018. For more information, visit http://www.uBiome.com.